Atlas Venture Fund XI, L.P.'s Form 4 filing
Xilio Therapeutics, Inc. (XLO) · filed Feb 9, 2024
- Accession no.
- 0001209191-24-003031
- Filed
- Feb 9, 2024, 4:33 PM ET
- Trade date
- Feb 8, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $640. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Atlas Venture Fund XI, L.P.CIK 0001708269 | 10% Owner |
| Atlas Venture Opportunity Fund I, L.P.CIK 0001759241 | 10% Owner |
| Atlas Venture Associates Opportunity I, L.P.CIK 0001780065 | 10% Owner |
| Atlas Venture Associates Opportunity I, LLCCIK 0001780066 | 10% Owner |
| Atlas Venture Associates XI, LLCCIK 0001780067 | 10% Owner |
| Atlas Venture Associates XI, L.P.CIK 0001780068 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 8, 2024 | Common Stock | SSaleDisposed | −733 | $0.64 | −$469.12 | 2,019,563 | Direct | |
| Feb 8, 2024 | Common Stock | SSaleDisposed | −267 | $0.64 | −$170.88 | 734,546 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.